Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
point decrease » point increase (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
-
2121
-
2122
-
2123
-
2124
-
2125
-
2126
-
2127
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
2128
-
2129
CHAMPS pilot Hb dataset.
Published 2025“…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
-
2130
-
2131
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2132
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2133
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2134
-
2135
-
2136
-
2137
-
2138
-
2139
-
2140